Global Clinical Laboratory Molecular Diagnostic for Infectious Disease Markets, Strategies, Trends and Forecasts 2023-2027 with Market Analysis & Executive Guides

DUBLIN, Feb. 26, 2024 /PRNewswire/ — The “Global Clinical Laboratory Molecular Diagnostic for Infectious Disease Markets. Strategies and Trends. Forecasts by Application (Transplant, Respiratory, etc.) by Country. With Market Analysis & Executive Guides. 2023 to 2027” report has been added to ResearchAndMarkets.com’s offering.

The Molecular Diagnostics – Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what’s happening in this informative report. And find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

Multiplex testingpathogen evolution and pandemicsbiotechnology advances in geneticsclimate changeglobalizationthe rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Make investment decisions and valuations with confidence using the latest data.

Key Topics Covered:

1 Market Guides
1.1 Situation Analysis
1.2 Market Shares of Leading Companies – Table and Chart

2 Introduction and Market Definition
2.1 Market Definition
2.1.1 Market Size
2.1.2 Currency
2.1.3 Years
2.2 Methodology
2.2.1 Methodology
2.2.2 Sources
2.2.3 Authors
2.3 Perspective: Healthcare and the IVD Industry
2.3.1 Global Healthcare Spending
2.3.2 Spending on Diagnostics
2.3.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases – Guide to the Pathogens
3.1 Infectious Disease Pathogens – The Big Picture
3.1.1 Viruses
3.1.2 Bacteria
3.1.3 Fungi
3.1.4 Parasites
3.1.5 Prions
3.1.6 Virulence
3.1.7 Transmission
3.2 The Coronavirus
3.2.1 Severe acute respiratory syndrome (SARS)
3.2.2 Middle East respiratory syndrome (MERS)
3.2.3 COVID-19. The SARS CoV 2 Virus.
3.2.3.1 Signs and symptoms
3.2.3.2 Transmission
3.2.3.3 Diagnosis
3.2.3.4 Prevention
3.2.3.5 Management
3.2.3.6 Prognosis
3.4 HIV – Human Immunodeficiency Virus (AIDS)
3.4.1 Virology
3.4.1.1 Classification
3.4.1.2 Structure and genome
3.4.1.3 Tropism
3.4.1.4 Replication cycle
3.4.1.5 Genetic variability
3.4.2 Diagnosis
3.4.3 Testing
3.4.3.1 Antibody tests
3.4.3.2 Point of Care Tests (POCT)
3.4.3.3 Antigen Tests
3.4.3.4 Nucleic acid-based tests (NAT)
3.4.3.5 Other tests used in HIV treatment
3.5 HBV – Hepatitis B
3.5.1 Virology
3.5.1.1 Genome
3.5.1.2 Pathogenesis
3.5.1.3 Hepatitis B virus replication
3.5.1.4 Serotypes and genotypes
3.5.2 Mechanisms
3.5.3 Diagnosis
3.5.4 Market Opportunity Analysis
3.6 HCV – Hepatitis C
3.6.1 Taxonomy
3.6.1.1 Structure
3.6.1.2 Genome
3.6.2 Molecular biology
3.6.3 Replication
3.6.4 Genotypes
3.6.4.1 Clinical importance
3.6.5 Market Opportunity Analysis
3.7 HPV – Human papillomavirus
3.7.1 Virology
3.7.1.1 E6/E7 proteins
3.7.1.2 Role in cancer
3.7.1.3 E2 research
3.7.1.4 Latency period
3.7.1.5 Clearance
3.7.2 Diagnosis
3.7.2.1 Cervical testing
3.7.2.2 Oral testing
3.7.2.3 Testing men
3.7.2.4 Other testing
3.7.3 Market Opportunity Analysis
3.8 Influenza
3.8.1 Virology
3.8.1.1 Types of virus
3.8.1.2 Influenzavirus A
3.8.1.3 Influenzavirus B
3.8.1.4 Influenzavirus C
3.8.1.5 Structure, properties, and subtype nomenclature
3.8.1.6 Replication
3.8.2 Testing
3.8.2.1 Advantages/Disadvantages of Molecular Assays
3.8.3 Market Opportunity Analysis
3.9 CTGC – Chlamydia/Gonorhea
3.9.1 Gonorrhea
3.9.1.1 Diagnosis
3.9.1.2 Screening
3.9.2 Chlamydia
3.9.2.1 Diagnosis
3.9.2.2 Screening
3.9.3 Testing
3.9.3.1 Nucleic acid amplification tests (NAATs).
3.9.3.2 Performance of NAAT Tests
3.9.4 Market Opportunity Analysis
3.10 Tuberculosis
3.10.1 Mycobacteria
3.10.2 Diagnosis
3.10.2.1 Active tuberculosis
3.10.2.2 Latent tuberculosis
3.10.3 Epidemiology
3.10.4 Molecular Diagnostic Tests
3.10.5 Market Opportunity Analysis
3.11 MRSA – Methicillin-resistant Staphylococcus aureus
3.11.1 Diagnosis
3.11.2 FDA Approved Molecular Tests
3.11.3 Market Opportunity Analysis
3.12 VRE – Vancomycin-resistant Enterococcus
3.12.1 FDA Approved MDx Tests for VRE
3.12.2 Market Opportunity Analysis

4 Industry Overview
4.1 Players in a Dynamic Market.
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Instrumentation Supplier
4.1.4 Chemical/Reagent Supplier
4.1.5 Pathology Supplier
4.1.6 Independent Clinical Laboratory
4.1.7 Public National/regional Laboratory
4.1.8 Hospital Laboratory
4.1.9 Physicians Office Lab (POLS)
4.1.10 Audit Body
4.1.11 Certification Body
4.2 The Clinical Laboratory Market Segments
4.2.1 Traditional Market Segmentation
4.2.2 Laboratory Focus and Segmentation
4.2.3 Segmenting the Syndromic Testing Market
4.3 Industry Structure
4.3.1 Hospital Testing Share
4.3.2 Economies of Scale
4.3.3 Hospital vs. Central Lab
4.3.4 Physician Office Lab’s
4.3.5 Physician’s and POCT

5 Market Trends
5.1 Factors Driving Growth
5.1.1 New Genotypes Creating New Markets
5.1.2 Aging Population a Boon for All Diagnostics
5.1.3 Developing World Driving ID Dx Growth
5.1.4 Point of Care – Why Centralization is Losing Steam
5.1.5 Self Testing
5.1.6 The Need for Speed
5.1.7 The COVID Pandemic
5.2 Factors Limiting Growth
5.2.1 Lower Costs
5.2.2 Infectious Disease is Declining
5.2.3 Wellness Hurts
5.2.4 Economic Growth Improves Living Standards
5.3 Instrumentation, Automation and Diagnostic Trends
5.3.1 Traditional Automation and Centralization
5.3.2 The New Automation, Decentralization and Point Of Care
5.3.3 Instruments Key to Market Share
5.3.4 Bioinformatics Plays a Role
5.3.5 PCR Takes Command
5.3.6 Next Generation Sequencing Fuels a Revolution
5.3.7 NGS Impact on Pricing
5.3.8 Whole Genome Sequencing, A Brave New World
5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments
6.1 Recent Developments – Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Spindiag Seeks Investors for Rapid PCR System
6.3 Sorrento Therapeutics Nabs Contract for Dx Platform
6.4 Kephera Planning Menu of Infectious Disease Tests
6.5 Oxford Nanopore and BioMerieux to Develop IDDx
6.6 SD Biosensor Eyes Global Expansion
6.7 Selux Dx Next Gen Phenotyping Gets FDA Clearance
6.8 Takara Developing High-Throughput Multiplex Panels
6.9 BioGX Debuts New Point-of-Care Molecular Testing System
6.10 Nanopath MDx Platform Providing 15-Minute Results
6.11 ProtonDx Commercializing Rapid MDx Instrument
6.12 Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform
6.13 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
6.14 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
6.15 Accelerate Diagnostics Anticipates Growth
6.16 Growth of Decentralized Testing Expected to Continue
6.17 Lumos Diagnostics Expanding Test Portfolio
6.18 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens
6.19 CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients
6.20 Accelerated Development of CRISPR as a Diagnostic Platform
6.21 Lab-on-a-Chip Infection Test Threatens Clinical Laboratory Role

7 Key Companies and Competitive Analysis
7.1 Abbott Laboratories
7.2 Beckman Coulter Diagnostics
7.3 Becton, Dickinson and Company
7.4 bioMerieux Diagnostics
7.5 Bio-Rad Laboratories, Inc.
7.6 Cepheid (Danaher)
7.7 Hologic
7.8 Ortho Clinical Diagnostics
7.9 Perkin Elmer.
7.10 Qiagen
7.11 Roche Molecular Diagnostics
7.12 Siemens Healthineers
7.13 Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/lgto2u

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected] 

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-clinical-laboratory-molecular-diagnostic-for-infectious-disease-markets-strategies-trends-and-forecasts-2023-2027-with-market-analysis–executive-guides-302070886.html

SOURCE Research and Markets